Histological and transcriptional characterization of the pancreatic acinar tissue in type 1 diabetes

Louise Granlund, Anders Hedin, Miriam Wahlhütter, Peter Seiron, Olle Korsgren, Oskar Skog, Marcus Lundberg

ABSTRACT

Introduction Despite a reduced function and volume of the exocrine pancreas in type 1 diabetes, the acinar cells remain understudied in type 1 diabetes research. The hypothesis of this study is that the acinar tissue is altered in subjects with type 1 diabetes compared with subjects without diabetes.

Research design and methods The cell density, expression of digestive enzymes, and transcriptome of acinar tissue at varying distances from islets were analyzed using histology, immunostaining, and AmpliSeq RNA sequencing of laser capture microdissected tissue. Pancreases examined were from organ donors with or without type 1 diabetes.

Results We demonstrate preserved acinar nuclei density and find no support of acinar atrophy in type 1 diabetes. Staining for digestive enzymes (amylase, lipase, and trypsin) demonstrated an evenly distributed expression in the exocrine parenchyma; although occasional amylase-negative regions appeared in tissue that had been formalin-fixed and paraffin-embedded, this phenomenon was not evident in frozen tissue. Gene set enrichment analysis of whole transcriptome data identified transcriptional alterations in type 1 diabetes that were present in the acinar tissue independent of the distance from islets. Among these, the two most enriched gene sets were Myc Targets V2 and Estrogen Response Early.

Conclusion Taken together, these new data emphasize the involvement of the entire pancreas in type 1 diabetes pathology. The alteration of the gene sets Myc Targets V2 and Estrogen Response Early is a possible link to the increased incidence of pancreatic cancer in type 1 diabetes.

INTRODUCTION

Classically described as a disease affecting the beta cells, type 1 diabetes has recently been recognized to involve the entire pancreas with reports of reduced pancreas volume and exocrine dysfunction. Other factors than an indirect effect of beta-cell loss. Acinar cells adjacent to islets devoid of insulin have been described by Foulis and Stewart to have severe atrophy, be smaller, and contain fewer zymogen granules. However, this association between acinar tissue atrophy and insulin-negative islets was not confirmed by Löhr and Klöppel who conversely reported a general atrophy of the acinar tissue in type 1 diabetes. Some studies were performed on autopsy material where the pancreas is exposed to various grades of autolysis. A more recent paper reported patches of amylase-negative regions in the exocrine pancreas as a common finding in non-diabetic subjects, with a reduced frequency in subjects with type 1 diabetes. Furthermore, Wright et al. reported a reduced pancreas volume in type 1 diabetes subjects due to reduced acinar cell numbers (with unaltered acinar cell size). Gepts reported in 1965 that acinar tissue in proximity to ducts is atrophic. The acinar tissue in type 1 diabetes has not been further described with molecular methods.

Significance of this study

What is already known about this subject?

-TYPE 1 DIABETES HAS RECENTLY BEEN RECOGNIZED TO INVOLVE THE ENTIRE PANCREAS WITH REPORTS OF REDUCED PANCREAS VOLUME AND EXOCRINE DYSFUNCTION.

What are the new findings?

-WE FIND NO HISTOLOGICAL SUPPORT OF ACINAR ATROPHY IN ACINAR TYPE 1 DIABETIC TISSUE BUT IDENTIFY ENRICHED GENE SETS INDEPENDENT OF THE DISTANCE FROM ISLETS.

How might these results change the focus of research or clinical practice?

-THIS PROVIDES FURTHER EVIDENCE OF THE INVOLVEMENT OF THE ENTIRE PANCREAS IN TYPE 1 DIABETES PATHOLOGY AND ENHANCE OUR UNDERSTANDING OF THE PATHOLOGY OF THE DISEASE.
The hypothesis tested in this study was that the acinar tissue is altered, on a histological and transcriptional level, in subjects with type 1 diabetes compared with subjects without diabetes. Additionally, we aimed to investigate whether such differences are particularly pronounced in exocrine regions in close proximity to islet tissue.

**RESEARCH DESIGN AND METHODS**

**Human pancreatic specimens**

Pancreases from heart-beating organ donors treated for organ transplantation were procured through the Nordic Network for clinical Islet Transplantation (https://nordicislets.medscinet.com/en.aspx). The pancreases were dissected, and biopsies were immediately fixed in 4% paraformaldehyde (PFA) or snap-frozen in liquid nitrogen and subsequently stored at −80°C. At the time of the study, the biobank contained biopsies from 12 donors with long-standing type 1 diabetes, with a disease duration of years, and more than 2000 non-diabetic donors. Frozen biopsies from all 12 donors with long-standing type 1 diabetes and non-diabetic donors that were age-matched, sex-matched, and BMI-matched to the type 1 diabetes donors were screened for CD45 infiltration and tissue quality.

Briefly, a 10 µm section cut with a cryostat (Leica, CM1860 UV, at −20°C) was double-stained for synaptophysin and CD45 (antibodies summarized in online supplemental table S1) using the EnVision G/2 Doublestain System, Rabbit/Mouse (diaminobenzidine (DAB)+/Permanent Red, Dako, Jena, Germany) and counterstained with hematoxylin (cat. nr. 01800, Histolab Products, Gothenburg, Sweden). Biopsies from three of the type 1 diabetes donors had an immune cell infiltration in exocrine tissue that was so pronounced that it would have substantially influenced the transcriptome analysis of acinar cells and were therefore excluded from further analysis. Biopsies from an additional two type 1 diabetes donors were excluded as they consisted mainly of adipose and fibrotic tissue, with a sparse number of islets and acinar tissue that could not be extracted with the utilized laser capture microdissection (LCM) protocol. Biopsies from the non-diabetic donors were similarly assessed for immune cell infiltration and tissue quality, excluding biopsies on the same basis as the type 1 diabetes donors, resulting in biopsies from eight donors being included for further examination. The characteristics of the 15 donors that passed screening and were included in the study are shown in online supplemental table S2. Five of the seven included donors with type 1 diabetes were also included in a previous study of islet characteristics. Formalin-fixed paraffin-embedded (FFPE) biopsies were histologically evaluated from the same donors.

**Immunohistochemistry and IF of acinar cells**

Sections (6 µm) from each FFPE tissue sample block were processed and labeled using a standard technique. The sections were stained for either synaptophysin or the exocrine enzymes amylase, trypsin, or lipase. All antibodies were unmasked by heat-induced antigen retrieval using EDTA according to the manufacturer’s instructions (Dako). Primary antibodies (online supplemental table S1) against synaptophysin, trypsin, lipase, or amylase were applied and thereafter visualized using Dako EnVision and DAB-based substrate. Three different antibodies targeting amylase were used in non-diabetic samples to validate possible findings, and thereafter one of the antibodies (HPA045394) was utilized in type 1 diabetes samples. Sections were counterstained with hematoxylin (Histolab) and analyzed using a light microscope (Leica DM2000 LED, Wetzlar, Germany) or Aperio ScanScope system (Aperio Technologies, Oxford, UK). The nucleus density (nuclei/mm²) was evaluated with assistance of ImageJ software on images obtained at 20× magnification. A minimum of five areas of two acinar regions, located either in direct proximity to islets (0–50 µm from islets, Exo1) or far from islets, defined as regions in areas where islets were not present, a minimum of 100 µm from islets (Exo3), were selected at random, and the number of nuclei were counted. On average, 811 nuclei were counted in every region of Exo1 and Exo3, respectively. The nuclei density was examined in all donors.

**Sectioning strategy of biopsies and immunofluorescent staining of endocrine cells**

The frozen biopsies that passed the screening were sectioned in consecutive series (10 µm per section). Every second section was prepared for LCM by mounting on Arcturus PEN Membrane Glass Slides (LCM0522, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored at −80°C until microdissection, generating a total of 10 LCM sections per biopsy. Of the remaining sections, every second was used for triple immunofluorescence (IF, see below for further information) of insulin, glucagon, and somatostatin or saved for future analysis (online supplemental figure S1). Four sections for IF and five additional slides were collected, mounted on Superfrost Plus glasses (Menzel-Gläser, Braunschweig, Germany), and stored at −80°C. The sections intended for endocrine cell IF staining were fixed in 4% PFA for 15 min, blocked with 5% normal goat serum (Dako) in 1× TBS-Tween (EnVision FLEX Wash Buffer, 20×, Dako) for 60 min, and incubated with anti-insulin, anti-glucagon, and anti-somatostatin antibodies (online supplemental table S1) diluted in 5% goat serum in 1× TBS-Tween for 60 min. Nuclei were stained with 500 nM SYTOX Orange nucleic acid stain. Slides were scanned on a confocal microscope (LSM700, Zeiss, Oberkochen, Germany). The scans were used to locate islets and scattered endocrine cells. This in turn was used to define acinar islet-adjacent areas and areas lacking endocrine cells that were microdissected on consecutive PEN membranes. The methodology was designed to only extract and study areas adjacent to insulin-negative islets in type 1 diabetes subjects, but it was discovered that all islets were insulin negative and therefore no selection was necessary.

Sections were stained for either synaptophysin or the exocrine enzymes amylase, trypsin, or lipase. All antibodies were unmasked by heat-induced antigen retrieval using EDTA according to the manufacturer’s instructions (Dako). Primary antibodies (online supplemental table S1) against synaptophysin, trypsin, lipase, or amylase were applied and thereafter visualized using Dako EnVision and DAB-based substrate. Three different antibodies targeting amylase were used in non-diabetic samples to validate possible findings, and thereafter one of the antibodies (HPA045394) was utilized in type 1 diabetes samples. Sections were counterstained with hematoxylin (Histolab) and analyzed using a light microscope (Leica DM2000 LED, Wetzlar, Germany) or Aperio ScanScope system (Aperio Technologies, Oxford, UK). The nucleus density (nuclei/mm²) was evaluated with assistance of ImageJ software on images obtained at 20× magnification. A minimum of five areas of two acinar regions, located either in direct proximity to islets (0–50 µm from islets, Exo1) or far from islets, defined as regions in areas where islets were not present, a minimum of 100 µm from islets (Exo3), were selected at random, and the number of nuclei were counted. On average, 811 nuclei were counted in every region of Exo1 and Exo3, respectively. The nuclei density was examined in all donors.
(online supplemental table S2), including the three type 1 diabetic donors that were excluded from the LCM analysis because of extensive immune cell infiltration in exocrine tissue. During the examination of the amylase staining pattern, acinar cell origin was verified by positive staining of trypsin and lipase (data not shown).

Frozen biopsies (online supplemental table S2) were sectioned (10µm) and fixed in 4% PFA for 15 min and then blocked with 5% normal goat serum (Dako) in 1× TBS-Tween (Dako) for 30 min. Primary antibodies against amylase and glucagon (online supplemental table S1) were diluted in 5% goat serum in 1× TBS-Tween, applied and incubated for 60 min after which the secondary antibody for amylase (online supplemental table S1) were diluted in 5% goat serum in 1× TBS-Tween, applied and incubated for 60 min. Nuclei were stained with 500 nM SYTOX Orange nucleic acid for 10 min. The sections were imaged on a confocal microscope (LSM700, Zeiss).

**Laser capture microdissection**

The samples were removed from −80°C, thawed and dehydrated using the following protocol: 75% EtOH for 30 s at −20°C, followed by 95% EtOH for 1 min, 100% EtOH for 1 min, and xylene for 4 min at room temperature (KIT0401, HistoGene LCM alcohol kit, Thermo Fisher Scientific). After drying, the membrane glass slides were mounted on an Arcturus XT LCM system (Thermo Fisher Scientific). The cap was subsequently incubated in 20 µL of Buffer RLT Plus (Qiagen, Sollentuna, Sweden) with 1% beta-Mercaptoethanol in a heating block for 30 min at 42°C, lysing the tissue. The lysates were stored at −80°C until RNA extraction. Areas of the cut regions were noted.

**RNA extraction**

The samples were brought to room temperature by short incubation at 37°C. All LCM-extracted samples were pooled for each respective tissue region for each donor. RNA was extracted with the RNeasy Plus Micro kit (Qiagen) according to the manufacturer’s protocol for purification of total RNA from microdissected cryosections. Samples were eluted with RNase-free water.

**AmpliSeq RNA sequencing**

For each sample, total RNA was reverse-transcribed to cDNA using the Ion AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher Scientific). The acquired cDNA was amplified using the Ion AmpliSeq Transcriptome Human Gene Expression core panel and adaptors (Ion P1 Adapter and Ion Xpress Barcode Adaptor) were ligated to the amplicons. Adaptor-ligated amplicons were purified using Agencourt AMPure XP reagents, eluted in amplification mix and amplified. Size selection and purification were conducted using Agencourt AMPure XP reagents. Sequencing of sample pools was then done in four separate runs using the Ion 550 Kit and the IonS5XL instrument (Thermo Fisher Scientific). Acquired reads were analyzed using the AmpliSeq RNA plugin in the Torrent Suite Server V.5.10.1. The reads were aligned to hg19 AmpliSeq Transcriptome ERCC V.1, quantifying expression data for 20813 genes. One sample (Exo2 from donor T1D-7) produced low quality reads and were excluded from further data analysis.

**Statistical analysis**

GraphPad Prism software (V.6.0h) was used for statistical analysis. The Mann-Whitney test was used to compare nuclei/mm² between non-diabetic and type 1 diabetes donors, whereas the Wilcoxon test was used to compare nuclei/mm² between Exo1 and Exo3 within the respective groups. A p value<0.05 was considered statistically significant.

**Filtering**

Data was analyzed using the edgeR R package (V. 3.28.1) starting from raw read counts. Genes with more than 10 counts per million in at least six samples were retained using the filterByExp function of edgeR.

**Deconvolution analysis**

Cell type proportions of the LCM-extracted bulk data were estimated with Multi-subject Single Cell (MuSiC) deconvolution using the R package MuSiC (V. 0.1.1). The raw counts were analyzed with the E-MTAB-5061 human pancreas single-cell data as reference dataset (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5061/). Results were visualized using ggplot2 (V. 3.3.0).

**Normalization**

Raw count normalization was performed using the trimmed mean of M values (TMM) method with the calcNormFactors function.

**Data structure**

TMM-adjusted and log-normalized counts were used to visualize the data structure of the acinar tissue by principal component analysis (PCA) using the R-package PCAtools.

**Differential gene expression analysis**

Differentially expressed genes (DEGs) between diabetic and non-diabetic donors for each acinar tissue region were analyzed using a generalized linear model and a quasi-likelihood test with the glmQLFit and glmTreat
functions of edgeR. Genes differentially expressed in type 1 diabetes compared with non-diabetic subjects were assessed. False discovery rate (FDR)-adjusted p values were calculated using the Benjamini-Hochberg method in the topTags function in edgeR. Criteria for differential expression was FDR-adjusted p value <0.05 while testing for an absolute log fold change ≥log2(1.2).

Functional enrichment analysis
Competitive gene set testing was conducted with CAMERA (Correlation Adjusted MEan RAnk test)\textsuperscript{28} using the camera function in edgeR\textsuperscript{22,23} and the MSigDB Hallmark set.\textsuperscript{29} A gene set was considered significantly enriched if the FDR-adjusted p value <0.25.

Data and resource availability
The datasets generated and analyzed during the current study are available in the GEO repository, GSE162689. No applicable resources were generated or analyzed during the current study.

RESULTS
Similar acinar cell density in pancreases from donors with or without type 1 diabetes regardless of the distance to islets
All islets in donors with type 1 diabetes were insulin-negative, although a few insulin-positive cells were found scattered in the exocrine parenchyma in 3/7 donors with type 1 diabetes (online supplemental table S2 and figure S2). The nuclei density (nuclei/mm\textsuperscript{2}) in acinar tissue was unaltered in donors with type 1 diabetes compared with non-diabetic donors, both in regions directly adjacent to islet tissue (Exo1) and in regions far away from the closest islet (Exo3) (figure 1A, B), although the interindividual difference was large. The mean acinar cell nuclei density was marginally higher in Exo1 than in Exo3 in the pancreas of non-diabetic subjects (figure 1C); however, no difference could be determined between Exo1 and Exo3 within the pancreas of type 1 diabetic subjects (figure 1D).

Amylase-negative acinar regions were found in FFPE but not in frozen tissue
Amylase-negative acinar regions (figure 2A–C), as described by Kusmartseva \textit{et al.}\textsuperscript{18} were found by immunohistochemistry (IHC) with three different antibodies against amylase on FFPE tissue. No amylase-negative acinar areas were found using IF on frozen tissue from the same donors (D). In FFPE sections, the amylase-negative areas were found both adjacent and non-adjacent to islets (white arrows). FFPE, formalin-fixed paraffin-embedded.
No clear clustering of samples based on disease status

To assess the presence of contaminating islet cells in the samples microdissected from different exocrine regions, cell type deconvolution of the transcriptome data was done. Samples extracted from the regions just adjacent to islet tissue (Exo1) were partly contaminated by islet tissue, both in type 1 diabetic and non-diabetic subjects, whereas samples extracted from regions further separated from islets (Exo2 and Exo3) had minimal contamination by islet tissue (figure 3A). A PCA of the 25% most variable genes across exocrine tissue shows no apparent clustering based on exocrine region or disease status (figure 3B).

Few DEGs were found in exocrine tissue of subjects with and without type 1 diabetes

In total, 29 DEGs in type 1 diabetes were found in exocrine regions (figure 4). Among these, 19 DEGs were overlapping with genes reported to be islet-enriched in at least one of four previous reports. The DEGs not overlapping with genes reported to be islet-enriched are marked in bold letters in figure 4D. Most of these were found in Exo1, in which 19 genes were downregulated and four upregulated in type 1 diabetes (figure 4A,D). In Exo2, two genes were downregulated and two genes were upregulated (figure 4B,D). In Exo3, two genes, TRIM9 and c6orf165, were downregulated in type one diabetes (figure 4C,D).

Similar gene sets were enriched in type 1 diabetes in all three exocrine regions

MSigDB Hallmark gene sets found to be enriched in type 1 diabetes in the different exocrine regions are displayed in table 1. Several gene sets were significantly enriched in all exocrine regions despite the limited number of DEGs. The two most enriched gene sets in type 1 diabetes for all exocrine regions (ie, Exo1, Exo2, and Exo3, respectively) were myc targets v2 (figure 5A) and estrogen response early (figure 5B), although the later was not significantly enriched in Exo2.

DISCUSSION

In this study, we found no difference in acinar nuclei density in type 1 diabetes compared with ND controls, contrasting with the general atrophy of acinar tissue described previously by Foulis and Stewart and Löhr and Klöppel. Both of these previous reports were based on studies of autopsy samples where autolysis must be considered as another possible explanation for the findings. A more recent paper by Wright et al reported unaltered acinar cell size in adult subjects with long-standing type 1 diabetes (duration 2–48 years), in line with our findings, and attributed the reduced pancreas volume in subjects with type 1 diabetes to a reduced number of acinar cells. Kusmartseva et al recently reported patches of amylase-negative regions in the exocrine pancreas as a common finding in non-diabetic subjects with a
reduced frequency in subjects with type 1 diabetes. Here, amylase-negative areas were found in only one non-diabetic subject and three type 1 diabetic subjects. However, the pattern was only seen with IHC on FFPE biopsies and could not be replicated with IF on frozen tissue sections. A possible interpretation is that the phenomenon is very local, appearing in some lobules but not others. An alternative explanation is that the amylase-negative regions are artifacts of formalin fixation and paraffin embedding.

In light of the exocrine dysfunction often reported in subjects with type 1 diabetes,\textsuperscript{9–13 18} we hypothesized that this would be reflected by alterations in the acinar transcriptome. Although the global expression profiles of the samples did not cluster by disease status, 23 type 1 diabetes DEGs were discovered in exocrine regions adjacent to the islets (Exo1). However, as MuSiC analysis revealed that this region was partly contaminated by islet cells, it is likely that at least some of these 23 DEGs are explained by the loss of beta-cells in type 1 diabetes. Indeed, some genes known to be beta-cell specific, such as INS and IAPP, were among the DEGs in Exo1. In the exocrine regions further away from islet tissue (Exo2 and Exo3), that were less affected by islet cell contamination, only few DEGs were detected. Despite the modest number

| Pathophysiology/complications |
|-------------------------------|

Figure 4  (A, B, C) Mean difference plots of genes, in type 1 diabetes compared with non-diabetic tissue of Exo1 (A), Exo2 (B), and Exo3 (C). Log2(fold change) was compared with average log2(CPM) of all type 1 diabetic and non-diabetic samples. Differentially expressed genes (DEGs) at an FDR-adjusted p value <0.05 and an absolute log fold change ≥log2(1.2) are highlighted. (D) DEGs at an FDR-adjusted p value <0.05 and an absolute log fold change ≥log2(1.2) in subjects with type 1 diabetes when compared with non-diabetic subjects in exocrine regions. CPM, counts per million; Exo1, region adjacent to islet; Exo2, region 50–100 µm from islet; Exo3, region in an area where islets were not present, a minimum of 100 µm from islets; FDR, false discovery rate.

| Table 2 |
|---------|

|        | Exo1         | Exo2         |
|--------|--------------|--------------|
|        | Downregulated| Upregulated  |
|        |              |              |
| INS    | PDK4         | TMEM201      |
| IAPP   |              |              |
| LRRTM3 | KLF15        |              |
| SYT16  | CRNN         |              |
| MAFA   |              |              |
| IFLTD1 |              |              |
| PLCH2  |              |              |
| PFKFB2 |              |              |
| SLC6A17|              |              |
| HAPLN4 |              |              |
| ADCYAP1|              |              |
| SLC05A1|              |              |
| TTC8   |              |              |
| HADH   |              |              |
| RGS16  |              |              |
| P2RY1  |              |              |
| ASB9   |              |              |
| G6PC2  |              |              |
| SLC18A2|              |              |
|        | Downregulated| Upregulated  |
|        |              |              |
| TRIM9  |              |              |
| C6orf165| C6orf165    |              |

*BMJ Open Diab Res Care 2021;9:e002076. doi:10.1136/bmjdr-2020-002076*
of DEGs, several gene sets were found to be significantly enriched in the acinar regions using gene set enrichment analysis. CAMERA was used to adjust for co-variation of prominent genes due to contamination, which may explain why the list of gene sets most enriched in Exo1 was similar to the list in Exo3, which was not contaminated by endocrine cells. These lists contained gene sets such as Myc Targets V2, Estrogen Response Early, Unfolded Protein Response, Adipogenesis, and TNFA signalling via NFkB. The same gene sets

| Table 1 | Gene sets found to be differentially expressed (FDR<0.25) in exocrine tissue between non-diabetic and type 1 diabetes subjects |
|---------|--------------------------------------------------------------------------------------------------------------------------|
| Gene set | N of genes | P value | FDR  |
| **Upregulated gene sets Exo1** | | | |
| HALLMARK_ESTROGEN_RESPONSE_EARLY | 171 | 0.000668 | 0.0277 |
| HALLMARK_MYC_TARGETS_V2 | 58 | 0.00111 | 0.0277 |
| HALLMARK_P53_PATHWAY | 172 | 0.00174 | 0.0290 |
| HALLMARK_ADIPOGENESIS | 180 | 0.00238 | 0.0297 |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB | 172 | 0.00471 | 0.0431 |
| HALLMARK_WNT_BETA_CATEMIN_SIGNALING | 35 | 0.00517 | 0.0430 |
| HALLMARK_MYC_TARGETS_V1 | 192 | 0.00794 | 0.0567 |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE | 106 | 0.0125 | 0.0694 |
| HALLMARK_CHOLESTEROL_HOMEOSTASIS | 68 | 0.0125 | 0.0694 |
| HALLMARK_HYPOXIA | 160 | 0.0156 | 0.0777 |
| HALLMARKHEME_METABOLISM | 161 | 0.0171 | 0.0777 |
| HALLMARK_UV_RESPONSE_UP | 136 | 0.0230 | 0.0959 |
| HALLMARK_XENOBIOTIC_METABOLISM | 162 | 0.0361 | 0.139 |
| HALLMARK_FATTY_ACID_METABOLISM | 141 | 0.0509 | 0.182 |
| HALLMARK_PROTEIN_SECRETION | 95 | 0.0672 | 0.210 |
| **Downregulated gene sets Exo1** | | | |
| HALLMARK_ALLOGRAFT_REJECTION | 149 | 0.0671 | 0.210 |
| **Upregulated gene sets Exo2** | | | |
| HALLMARK_MYC_TARGETS_V2 | 58 | 0.00347 | 0.174 |
| **Downregulated gene sets Exo2** | | | |
| **Upregulated gene sets Exo3** | | | |
| HALLMARK_MYC_TARGETS_V2 | 58 | 0.000386 | 0.0181 |
| HALLMARK_ESTROGEN_RESPONSE_EARLY | 171 | 0.000722 | 0.0181 |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE | 106 | 0.00239 | 0.0398 |
| HALLMARK_ADIPOGENESIS | 180 | 0.00408 | 0.0409 |
| HALLMARK_MYC_TARGETS_V1 | 192 | 0.00409 | 0.0409 |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB | 172 | 0.00535 | 0.0446 |
| HALLMARK_HEME_METABOLISM | 161 | 0.0112 | 0.0705 |
| HALLMARK_WNT_BETA_CATEMIN_SIGNALING | 35 | 0.0137 | 0.0705 |
| HALLMARK_HYPOXIA | 160 | 0.0138 | 0.0705 |
| HALLMARK_FATTY_ACID_METABOLISM | 141 | 0.0165 | 0.0705 |
| HALLMARK_PROTEIN_SECRETION | 95 | 0.0167 | 0.0705 |
| HALLMARK_XENOBIOTIC_METABOLISM | 162 | 0.0169 | 0.0705 |
| HALLMARK_P53_PATHWAY | 172 | 0.0202 | 0.0779 |
| HALLMARK_UV_RESPONSE_UP | 136 | 0.0253 | 0.0903 |
| HALLMARK_OXIDATIVE_PHOSPHORYLATION | 177 | 0.0472 | 0.1574 |
| HALLMARK_GLYCOLYSIS | 169 | 0.0526 | 0.164 |
| **Downregulated gene sets Exo3** | | | |
| - | - | - | - |

FDR, false discovery rate.
Pathophysiology/complications

were also present among the top ranked in Exo2 although not statistically significant. In summary, this suggests that there were a general transcriptional alteration present in acinar type 1 diabetes tissue that did not depend on the distance from islets. As illustrated in the heatmaps of the most enriched pathways Myc Targets V2 and Estrogen Response Early, small expression alterations in several genes most likely explain the enrichment of the gene sets, rather than large variations in a limited number of genes.

c-MYC is a proto-oncogene involved in many cellular processes such as cell growth, proliferation, and apoptosis. The transcription factor has been demonstrated to play a crucial role in pancreas development and differentiation but also the progression of pancreatic cancer. Diabetes and hyperglycemia have been linked to an increased risk of developing pancreatic cancer. In a recent study by Sato et al, a link is shown between hyperglycemia, the activation of MYC through STAT3, and the development
of pancreatic cancer.\textsuperscript{36} Similarly, estrogen receptor-related pathways have been linked to an increased risk of developing pancreatic cancer.\textsuperscript{37–39} Alternatively, the activation of c-MYC and estrogen response genes could be a compensatory response to the reduced acinar volume\textsuperscript{38} to initiate proliferation of the tissue.

In conclusion, transcriptional alterations were present in the acinar tissue seemingly independent of the distance from islets. Two gene sets were enriched in all exocrine regions: Myc Targets V2 and Estrogen Response Early. The alteration of these genes is a possible link to the increased incidence of pancreatic cancer in type 1 diabetes, which merits further investigation.

Acknowledgements We wish to thank everyone in the Nordic Network for Clinical Islet Transplantation involved in the procurement of pancreases. We also give our deepest gratitude to all organ donors. Support by NBIS (National Bioinformatics Infrastructure Sweden) is gratefully acknowledged. We also thank Gajana Gasparyan and Sofie Ingvast for excellent technical assistance.

Contributors All authors participated in designing the study and writing the manuscript. LG, MW, and ML performed experiments. LG, MW, AH, PS, and ML analyzed data. LG, AH, PS, OK, OS, and ML interpreted and evaluated the data. LG and ML are the guarantors of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of the manuscript. OS and MS are shared last authors.

Funding This study was supported by a junior grant to ML from the Diabetes Wellness Sweden. The study was further supported by the Family Emfors Foundation, the Novo Nordisk Foundation, the Åke Wiberg Foundation, the Tore Nilsson Foundation, the Swedish Diabetes Association, Gillbergska Stiftelsen, Barndiabetesfonden and the Swedish Medical Research Council (2019-01415 and 2K2015-54X-12219-19-4). Human pancreatic biopsies were obtained from the Nordic Network for Clinical Islet Transplantation, supported by the Swedish national strategic research initiative Excellence of Diabetes Research in Sweden (EXODIAB) and the Juvenile Diabetes Research Foundation.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Consent for organ donation was obtained verbally from the deceased’s next of kin by the attending physician and was documented in accordance with Swedish law and as approved by the Regional Ethics Committee (DNR 2015/444).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. The datasets generated and analyzed during the current study are available in the GEO repository, GSE162689. No applicable resources were generated or analyzed during the current study.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Louise Granlund http://orcid.org/0000-0002-2888-486X

REFERENCES

1. Korsgren S, Molin Y, Salmela K, et al. On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response.\textit{Am J Pathol} 2012;181:1735–48.

2. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulitis and \textit{j}-cell mass in the natural history of type 1 diabetes.\textit{Diabetes} 2016;65:719–31.

3. Campbell-Thompson M, Wasserman C, Montgomery EL, et al. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes.\textit{JAMA} 2012;308:2337–9.

4. Gaglia JL, Guimaraes AR, Harisinghmani M, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients.\textit{J Clin Invest} 2011;121:442–5.

5. Lörh M, Köppel G. Residual insulin positivity and pancreatic atrophy in patients with diabetes.\textit{Diabetes} 2012;61:29–37.

6. Williams AJK, Chau W, Callaway MP, et al. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in type 1 diabetes.\textit{Diabet Med} 2007;24:35–40.

7. Williams AJK, Thrower SL, Sequeiros IM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes.\textit{J Endocrinol Invest} 2012;35:971–9.

8. Bahri S, Graybiel AM, Hennicke JC. Cellular composition of the human diabetic pancreas.\textit{Diabetologia} 1983;24:366–71.

9. Augustin P, Gent R, Louise J, et al. Pancreas size and exocrine function is decreased in young children with recent-onset type 1 diabetes.\textit{Diabet Med} 2020;37:1340–3.

10. Campbell-Thompson M, Rodriguez-Calvo T, Battaglia M. Abnormalities of the exocrine pancreas in type 1 diabetes.\textit{Curr Diab Rep} 2015;15:79.

11. Hardt PD, Krauss A, Bretz L, et al. Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus.\textit{Acta Diabetol} 2000;37:105–10.

12. Kondrashova A, Nurminen N, Lehtonen J, et al. Exocrine pancreas function decreases during the progression of the beta-cell damaging process in young prediabetic children.\textit{Pediatr Diabetes} 2018;19:398–402.

13. Langer E, Philippe MF, Barbot-Trystram L, et al. Pancreatic exocrine function in patients with diabetes.\textit{Diabetologia} 2012;55:1047–54.

14. Foster TR, Bruggeman B, Campbell-Thompson M, et al. Exocrine pancreas dysfunction in type 1 diabetes.\textit{Endocr Pract} 2020;26:1505–13.

15. Henderson JR, Daniel PM, Fraser PA. The pancreas as a single organ: the influence of the endocrine upon the exocrine part of the gland.\textit{Gut} 1981;22:158–67.

16. Vecchio F, Messina G, Giovenzana A, et al. New evidence of exocrine Pancreatopathy in pre-symptomatic and symptomatic type 1 diabetes.\textit{Curr Diab Rep} 2019;19:92.

17. Foulis AK, Stewart JA. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue.\textit{Diabetologia} 1984;26:456–61.

18. Kusmartseva I, Beery M, Hiller H, et al. Temporal analysis of amylose expression in control, Autoantibody-Positive, and type 1 diabetes pancreatic tissues.\textit{Diabetes} 2020;69:60–6.

19. Wright JJ, Saunders DC, Dai C, et al. Decreased pancreatic acinar cell number in type 1 diabetes.\textit{Diabetologia} 2020;63:1418–23.

20. Gupta W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus.\textit{Diabetes} 1965;14:619–33.

21. Seirón P, Wiberg A, Kuric E, et al. Characterisation of the exocrine pancreas in type 1 diabetes: islet size is maintained but islet number is markedly reduced.\textit{J Pathol Clin Res} 2019;5:248–55.

22. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation.\textit{Nucleic Acids Res} 2012;40:4288–97.

23. Robinson MD, McCarthy DJ, Smyth GK, edgeR: A Bioconductor package for differential expression analysis of digital gene expression data.\textit{Bioinformatics} 2012;28:139–40.

24. Wang X, Park J, Susztak K, et al. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference.\textit{Nat Commun} 2019;10:380.

25. Segerstolpe Åsa, Palasantza A, Eliasson P, et al. Single-Cell transcription profiling of human pancreatic islets in health and type 2 diabetes.\textit{Cell Metab} 2016;24:593–607.

Peter Seirón http://orcid.org/0000-0002-1419-450X

Oskar Skog http://orcid.org/0000-0001-9713-722X

Marcus Lundberg http://orcid.org/0000-0001-7916-2327
Pathophysiology/complications

26 Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-Seq data. *Genome Biol* 2010;11:R25.

27 Bligh K. kevinblighe/PCAtools, 2020.

28 Oxford academic. Camera: a competitive gene set test accounting for inter-gene correlation | nucleic acids research. Available: https://academic.oup.com/nar/article/40/17/e133/2411151

29 Liberzon A, Birger C, Thorvaldsdottir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. *Cell Syst* 2015;1:417–25.

30 Xin Y, Kim J, Okamoto H, et al. Rna sequencing of single human islet cells reveals type 2 diabetes genes. *Cell Metab* 2016;24:608–15.

31 Muraro MJ, Dharmadhikari G, Grün D, et al. A single-cell transcriptome atlas of the human pancreas. *Cell Syst* 2016;3:385–94.

32 Lawlor N, George J, Bolisetty M, et al. Single-Cell transcriptomes identify human islet cell signatures and reveal cell-type-specific expression changes in type 2 diabetes. *Genome Res* 2017;27:208–22.

33 Skoudy A, Hernández-Muñoz I, Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-myc. *J Gastrointest Cancer* 2011;42:76–84.

34 Schleger C, Verbeke C, Hildenbrand R, et al. C-Myc activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. *Mod Pathol* 2002;15:462–9.

35 Sato K, Hikita H, Myojin Y, et al. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and Myc levels. *PLoS One* 2020;15:e0235573.

36 Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. *The Lancet* 2020;395:2008–20.

37 Pozios I, Knüsel T, Zhao Y, et al. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. *J Cancer Res Clin Oncol* 2018;144:1887–97.

38 Seeliger H, Pozios I, Assmann G, et al. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. *BMC Cancer* 2018;18:1049.

39 Konduri S, Schwarz RE. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. *J Surg Res* 2007;140:55–66.